Corporate - Media & Press - Press Release
Major News Media Missed the Mark -- There Is a New Pre-Symptomatic Screening Test for Ovarian Cancer Coming From Arrayit Corporation, and It Will Be Available Soon
Noninvasive Test Will Provide Hope for 90% of Women Diagnosed With This Silent Killer
Press Release Source: Arrayit Corporation On Thursday January 7, 2010, 7:00 am EST
SUNNYVALE, CA--(Marketwire - 01/07/10) - On December 9th, 2009, Arrayit Corporation (OTC.BB:ARYC - News), a leading manufacturer of products and services for disease prevention, treatment and cure, announced a breakthrough in ovarian cancer screening utilizing a microarray-based diagnostic test that will detect whether a patient is pre-symptomatic for this silent killer.
In a report by NBC's Dr. Robert Bezell on Tuesday, January 5th, it was reported that although research continues, there is no effective screening test currently available to detect the pre-symptomatic presence of ovarian cancer. The report missed the mark, which indicates that press information distributed by Arrayit on December 9th, somehow fell through the cracks. The fact is, Arrayit's advanced screening test, OvaDx(TM), will be available very soon.
Researchers at a major cancer research institute have worked for six years to identify more than 100 biomarkers unique to ovarian cancer. The proteomic markers were finally identified using a novel and patented microarray platform created by Arrayit. A noninvasive screening test can be performed via a simple blood test that can be conducted during annual physical exams. The test will soon be submitted to the FDA for approval, and since it is an in vitro diagnostic multivariate index assay, prompt approval is anticipated.
According to the American Cancer Society, more than 21,500 women will be diagnosed with Ovarian Cancer this year, and 14,000 will die. Up until now, screening tests could only detect the 'Silent Killer' when the disease is symptomatic, meaning the disease has progressed to stage 3 or 4. Unfortunately at this late stage of detection the cancer most certainly has metastasized and spread beyond the ovary, which proves fatal for 75% of women diagnosed.
Ovarian cancer ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of the female reproductive system. Clinicians state that the primary reasons for such a high fatality rate are that there are no discernable early symptoms, and there has not been an effective early detection test available. The American Cancer Society estimates that 90% of woman diagnosed with ovarian cancer could survive with early detection. Currently only 20% of women diagnosed are in the early stages.
The early detection of ovarian cancer holds tremendous potential to profoundly impact the quality of life of ovarian cancer victims and shift costs from treatment to detection ensuring survivability for a larger population. Upon FDA approval, OvaDx(TM) will be marketed and sold by Arrayit Corporation's subsidiary, Arrayit Diagnostics (Ovarian), Inc., in Houston, Texas under a licensing agreement.
Arrayit Corporation (OTC.BB:ARYC - News), headquartered in Sunnyvale, California, leads and empowers the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure. Arrayit now offers over 650 products to a customer base of more than 10,000 clinics and research facilities, and more than 5,000 laboratories worldwide, including most every major university, pharmaceutical and biotech company, major agricultural and chemical company, government agency, national research foundation and many private sector enterprises. Please visit www.arrayit.com for more information.
Safe Harbor Statement
Except for historical information contained herein, statements made in this release that constitute forward-looking statements are based on currently available information, involve certain risks and uncertainties and the Company assumes no responsibility to update any such forward-looking statement. The following factors, among others, may cause actual results to differ materially from the results suggested in the forward-looking statements. Risks that may result from changes in the Company's business operations; our ability to keep pace with technological advances; significant competition in the biomedical business; our relationships with key suppliers and customers; quality and consumer acceptance of newly introduced products; market volatility; non-availability of product; excess inventory; price and product competition; new product introductions, the outcome of our legal disputes; the possibility that the review of our prior filings by the SEC may result in changes to our financial statements; and the possibility that stockholders or regulatory authorities may initiate proceedings against Arrayit and/or our officers and directors as a result of any restatements. Risk factors associated with our business, including some of the facts set forth herein, are detailed in the Company's Form 10-K/A for the fiscal year ended December 31, 2008 and Form 10-Q/A for the fiscal first quarter ended March 31, 2009, Form 10-Q/A for the fiscal second quarter ended June 30, 2009 and Form 10-Q for the fiscal third quarter ended September 30, 2009.
Copyright 1993-2018 Arrayit Corporation. All rights reserved.